<DOC>
	<DOCNO>NCT01539707</DOCNO>
	<brief_summary>The purpose study evaluate blood level solifenacin succinate ( study drug ) child neurogenic detrusor overactivity take single oral dose . If bladder contract strongly without warn , muscle surround urethra ( detrusor muscle ) may able keep urine passing . This may happen consequence spinal cord defect , call neurogenic detrusor overactivity .</brief_summary>
	<brief_title>Single Dose Study Measure Blood Levels Safety Drug Children With Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Documented diagnosis NDO , confirm urodynamics Weight height within normal percentile ( 3rd 97th percentile ) accord Centers Disease Control Prevention ( CDC ) growth chart Subject 's bowel function actively manage Able swallow study medication accordance protocol Female subject childbearing potential sexually active agree use reliable form birth control duration study least one month end study treatment . Sexually active male subject agree use barrier method birth control duration study least one month end study treatment Subject subject 's parent ( ) /legal guardian willing able comply study requirement concomitant medication restriction At screening : Subject breastfeeding pregnant . Subjects childbearing potential must negative serum pregnancy test Subject follow gastrointestinal ( GI ) condition : partial complete bowel obstruction , decrease motility ( e.g. , paralytic ileus ) risk gastric retention Current fecal impaction history hospitalization fecal impaction enema past 2 year History QTc prolongation risk QT prolongation ( e.g. , hypokalemia , family history Long QT Syndrome [ LQTS ] ) . QT interval great 470 m baseline Any clinically significant abnormality ECG History current diagnosis malignancy Diagnosis central X chromosomelinked diabetes insipidus Cystatine C great equal 2 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) great equal 2 time ULN total bilirubin great equal 1.5 time ULN Any clinically significant range result urinalysis , biochemistry hematology Known suspect hypersensitivity solifenacin ( anticholinergic ) , excipients use current formulation previous severe hypersensitivity drug Subject participate another clinical trial and/or take investigational drug within 30 day ( 5 halflives drug whichever longer ) prior Day 1 Requires ongoing treatment follow prohibited medication : antimuscarinic therapy , tricyclic/tetracyclic antidepressant , H1 antihistamine , strong CYP3A4 inhibitor , strong CYP3A4 inducer ( many antiepileptic drug like carbamazepine , phenytoin phenobarbital ) Mean systolic blood pressure great 95th percentile accord age height and/or great 140 mmHg [ National Institute Health , 2005 ] , judge clinically significant investigator Subject 's parent ( ) /legal guardian employee Astellas Group , Contract Research Organization ( CRO ) involve , investigator site execute study At Day 1 : Consumption grapefruit product make ( e.g. , juice ) , Seville oranges product make ( e.g. , marmalade ) within 14 day prior Day 1 Positive drug screen test drug abuse Day 1 Positive alcohol breath test Day 1 Use prohibit prior concomitant medication : Antimuscarinics , tricyclic/tetracyclic antidepressant , H1 antihistamine within 5 halflives prior intake study drug Day 1 Prescribed counter ( OTC ) drug potent cytochrome P450 ( CYP ) 3A4 inhibitor ( e.g. , ketoconazole ) , CYP3A4 substrates high affinity ( e.g. , verapamil , diltiazem ) , potent CYP3A4 inducer ( e.g. , rifampicin , phenytoin , carbamazepine ) , include natural herbal remedy ( e.g. , St. John 's Wort ) within 14 day prior intake study drug Day 1 Donation blood blood product within 3 month prior Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Neurogenic Detrusor Overactivity</keyword>
	<keyword>Solifenacin succinate suspension</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Phase 1</keyword>
</DOC>